Initial sequencing and analysis of the human genome US DOE Joint Genome Institute: Hawkins Trevor 4 Branscomb Elbert 4 Predki ... nature 409 (6822), 860-921, 2001 | 30279 | 2001 |
A 1.1-Mb transcript map of the hereditary hemochromatosis locus DA Ruddy, GS Kronmal, VK Lee, GA Mintier, L Quintana, R Domingo, ... Genome research 7 (5), 441-456, 1997 | 113 | 1997 |
Specific stereochemistry of OP-1074 disrupts estrogen receptor alpha helix 12 and confers pure antiestrogenic activity SW Fanning, L Hodges-Gallagher, DC Myles, R Sun, CE Fowler, IN Plant, ... Nature communications 9 (1), 2368, 2018 | 47 | 2018 |
Genoviz Software Development Kit: Java tool kit for building genomics visualization applications GA Helt, JW Nicol, E Erwin, E Blossom, SG Blanchard, SA Chervitz, ... BMC bioinformatics 10, 1-13, 2009 | 35 | 2009 |
Benzopyran compounds, compositions and uses thereof PJ Kushner, DC Myles, CL Harmon, LCH Gallagher US Patent 9,018,244, 2015 | 24 | 2015 |
System, method, and computer program product for the representation of biological sequence data G Helt, C Harmon US Patent App. 10/423,530, 2004 | 23 | 2004 |
Comparative Analysis of Spatial Patterns of Gene Expression in Drosophila melanogaster Imaginal Discs CL Harmon, P Ahammad, A Hammonds, R Weiszmann, SE Celniker, ... Annual International Conference on Research in Computational Molecular …, 2007 | 20 | 2007 |
Joint nonparametric alignment for analyzing spatial gene expression patterns in Drosophila imaginal discs P Ahammad, CL Harmon, A Hammonds, SS Sastry, GM Rubin 2005 IEEE Computer Society Conference on Computer Vision and Pattern …, 2005 | 16 | 2005 |
Substituted triphenyl butenes P Kushner, C Harmon, D Myles US Patent 8,063,249, 2011 | 12 | 2011 |
Abstract P1-17-12: preliminary data from a phase I/II, multicenter, dose escalation study of OP-1250, an oral CERAN/SERD, in subjects with advanced and/or metastatic estrogen … M Patel, C Alemany, Z Mitri, D Makower, V Borges, J Sparano, T Le, ... Cancer Research 82 (4_Supplement), P1-17-12-P1-17-12, 2022 | 10 | 2022 |
OP-1250: A potent orally available complete antagonist of estrogen receptor-mediated signaling that shrinks wild type and mutant breast tumors L Hodges-Gallagher, R Sun, D Myles, P Klein, JA Zujewski, C Harmon, ... European Journal of Cancer 138, S55, 2020 | 6 | 2020 |
OP-1250 is a Complete Estrogen Receptor Antagonist (CERAN) that Lacks Agonist Activity on Cell Signaling and Proliferation in Breast Cancer Cells L Hodges-Gallagher, R Sun, DC Myles, CL Harmon, PJ Kushner, ... Apoptosis (GO. 0006915) 4, 6, 2020 | 5 | 2020 |
Anti-estrogenic compounds PJ Kushner, DC Myles, CL Harmon, LCH GALLAGHER US Patent App. 15/135,840, 2016 | 5 | 2016 |
Preliminary data from a phase 1/2, multicenter, dose escalation study of OP-1250, an oral CERAN/SERD, in patients with advanced and/or metastatic estrogen receptor (ER … M Patel, C Alemany, Z Mitri, D Makower, V Borges, J Sparano, T Le, ... Cancer Res 82 (4_Supplement), P1-17-12, 2022 | 4 | 2022 |
OP-1250, a complete estrogen receptor antagonist (CERAN) that shrinks estrogen receptor positive tumors and exhibits favorable pharmacokinetics L Hodges-Gallagher, CL Harmon, R Sun, DC Myles, P Kushner Cancer Research 80 (16_Supplement), 4376-4376, 2020 | 4 | 2020 |
Tetrahydro-1H-pyrido [3, 4-b] indole anti-estrogenic drugs DC Myles, PJ Kushner, CL Harmon US Patent 10,624,878, 2020 | 4 | 2020 |
Abstract P5-05-02: preclinical development of OP-1250, an oral complete estrogen receptor antagonist (CERAN) that shrinks ER-positive breast tumors in xenograft models L Hodges-Gallagher, R Sun, DC Myles, CL Harmon, PJ Kushner Cancer Research 80 (4_Supplement), P5-05-02-P5-05-02, 2020 | 3 | 2020 |
Tetrahydro-1H-pyrido [3, 4-b] indole anti-estrogenic drugs DC Myles, PJ Kushner, CL Harmon US Patent 10,292,971, 2019 | 3 | 2019 |
Abstract P2-24-07: Combination of complete estrogen receptor antagonist, OP-1250, and CDK4/6 inhibitors enhances tumor suppression and inhibition of cell cycle-related gene … AD Parisian, GS Palanisamy, F Ortega, JL Sapugay, WJ Bodell, D Kulp, ... Cancer Research 83 (5_Supplement), P2-24-07-P2-24-07, 2023 | 2 | 2023 |
Abstract LB122: the complete estrogen receptor antagonist (CERAN) OP-1250 shrinks ER+ brain metastases in an intracranial xenograft tumor model expressing mutant ESR1 L Hodges-Gallagher, AD Parisian, R Sun, DC Myles, PM Klein, ... Cancer Research 81 (13_Supplement), LB122-LB122, 2021 | 2 | 2021 |